A Whole Body Counter for Serial Studies of Total Body Potassium

1970 ◽  
Vol 39 (2) ◽  
pp. 319-326 ◽  
Author(s):  
K. V. Johny ◽  
B. W. Worthley ◽  
J. R. Lawrence ◽  
M. W. O'Halloran
Keyword(s):  
Clinical Studies ◽  
Normal Subjects ◽  
Whole Body ◽  
Total Body Potassium ◽  
Body Counter ◽  
Whole Body Counter ◽  
Total Body ◽  
Counting Statistics ◽  
Normal Variability

1. The use of a whole body counter in total body potassium estimations is described. The accuracy and value of the counter in measuring serial changes in total body potassium was assessed. 2. Serial study of twelve normal subjects at varying intervals revealed a normal variability in total body potassium of up to 1·23% (4-weekly measurements over 3 months). The error involved in counting statistics alone was 4%. 3. The whole body counter appears to be an accurate and useful method of assessing total body potassium in clinical studies.

Measurements of the Total-body Potassium Contents: Application of Reference Value with the Whole-body Counter.

RADIOISOTOPES ◽  
2001 ◽  
Vol 50 (8) ◽  
pp. 331-342
Author(s):  
Tetsuo YAMAMOTO ◽  
Kenji SAEGUSA ◽  
Noboru ARIMIZU ◽  
Yoshio KUNIYASU ◽  
Hisao ITOH
Keyword(s):  
Reference Value ◽  
Whole Body ◽  
Total Body Potassium ◽  
Body Counter ◽  
Whole Body Counter ◽  
Total Body

Measurement of Total Body Potassium in Premature Infants by Means of a Whole-Body Counter

1986 ◽  
Vol 5 (5) ◽  
pp. 750-755 ◽  
Author(s):  
Donald W. Spady ◽  
Larry J. Filipow ◽  
Thomas R. Overton ◽  
Waldemar A. Szymanski
Keyword(s):  
Premature Infants ◽  
Whole Body ◽  
Total Body Potassium ◽  
Body Counter ◽  
Whole Body Counter ◽  
Total Body

scholarly journals Correlation of total body potassium and leukemic cell mass in patients with chronic lymphocytic leukemia

Blood ◽  
1979 ◽  
Vol 53 (4) ◽  
pp. 594-603
Author(s):  
P Chandra ◽  
A Sawitsky ◽  
AD Chanana ◽  
G Chikkappa ◽  
SH Cohn ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Cell Mass ◽  
Leukemic Cell ◽  
Lymphocytic Leukemia ◽  
Clinical Staging ◽  
Whole Body ◽  
Total Body Potassium ◽  
Body Counter ◽  
Whole Body Counter ◽  
Total Body

Total body leukemic mass in patients with chronic lymphocytic leukemia (CLL) was measured by quantitation of total body potassium (TBK) with a whole-body counter. In addition, the predicted normal total body potassium (Kp) for each patient was calculated from an empirically derived relationship involving height, weight, age, and sex. Both the absolute TBK and the relative excess of total body potassium (TBK/Kp) were related to the stage of disease. Patients in the early stages of CLL were found to have lower TBK and TBK Kp than patients in the late stages of disease. Both of these parameters increased with the successively advanced stages of the disease. The clinically monitored reduction of leukemic cell mass following therapy was accompanied by reductions in TBK and TBK/Kp. Data presented support the notion that TBK/Kp is a useful indicator of the total body leukemic mass. Furthermore, the results of these studies quantitatively validate the proposed clinical staging system for CLL. Quantitation of TBK by a whole-body counter is an accurate and noninvasive procedure and does not require administration of isotopes.

Correlation of total body potassium and leukemic cell mass in patients with chronic lymphocytic leukemia

Blood ◽  
1979 ◽  
Vol 53 (4) ◽  
pp. 594-603 ◽  
Author(s):  
P Chandra ◽  
A Sawitsky ◽  
AD Chanana ◽  
G Chikkappa ◽  
SH Cohn ◽  
...  
Keyword(s):  
Chronic Lymphocytic Leukemia ◽  
Cell Mass ◽  
Leukemic Cell ◽  
Lymphocytic Leukemia ◽  
Clinical Staging ◽  
Whole Body ◽  
Total Body Potassium ◽  
Body Counter ◽  
Whole Body Counter ◽  
Total Body

Abstract Total body leukemic mass in patients with chronic lymphocytic leukemia (CLL) was measured by quantitation of total body potassium (TBK) with a whole-body counter. In addition, the predicted normal total body potassium (Kp) for each patient was calculated from an empirically derived relationship involving height, weight, age, and sex. Both the absolute TBK and the relative excess of total body potassium (TBK/Kp) were related to the stage of disease. Patients in the early stages of CLL were found to have lower TBK and TBK Kp than patients in the late stages of disease. Both of these parameters increased with the successively advanced stages of the disease. The clinically monitored reduction of leukemic cell mass following therapy was accompanied by reductions in TBK and TBK/Kp. Data presented support the notion that TBK/Kp is a useful indicator of the total body leukemic mass. Furthermore, the results of these studies quantitatively validate the proposed clinical staging system for CLL. Quantitation of TBK by a whole-body counter is an accurate and noninvasive procedure and does not require administration of isotopes.

Sign in / Sign up

Export Citation Format

Share Document